FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386119477> ?p ?o ?g. }

• W4386119477 abstract "Abstract Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the association between major adverse cardiovascular events (MACE) and baseline kidney parameters and whether the effect of semaglutide on MACE risk was impacted by baseline kidney parameters in people with T2D at high cardiovascular risk. Methods Participants from the SUSTAIN 6 and PIONEER 6 trials, receiving semaglutide or placebo, were categorised according to baseline kidney function (estimated glomerular filtration rate [eGFR] < 45 and ≥ 45–<60 versus ≥ 60 mL/min/1.73 m 2 ) or damage (urine albumin:creatinine ratio [UACR] ≥ 30–≤300 and > 300 versus < 30 mg/g). Relative risk of first MACE by baseline kidney parameters was evaluated using a Cox proportional hazards model. The same model, adjusted with inverse probability weighting, and a quadratic spline regression were applied to evaluate the effect of semaglutide on risk and event rate of first MACE across subgroups. The semaglutide effects on glycated haemoglobin (HbA 1c ), body weight (BW) and serious adverse events (SAEs) across subgroups were also evaluated. Results Independently of treatment, participants with reduced kidney function (eGFR ≥ 45–<60 and < 45 mL/min/1.73 m 2 : hazard ratio [95% confidence interval]; 1.36 [1.04;1.76] and 1.52 [1.15;1.99]) and increased albuminuria (UACR ≥ 30–≤300 and > 300 mg/g: 1.53 [1.14;2.04] and 2.52 [1.84;3.42]) had an increased MACE risk versus those without. Semaglutide consistently reduced MACE risk versus placebo across all eGFR and UACR subgroups (interaction p value [p INT ] > 0.05). Semaglutide reduced HbA 1c regardless of baseline eGFR and UACR (p INT >0.05); reductions in BW were affected by baseline eGFR (p INT <0.001) but not UACR (p INT >0.05). More participants in the lower eGFR or higher UACR subgroups experienced SAEs versus participants in reference groups; the number of SAEs was similar between semaglutide and placebo arms in each subgroup. Conclusions MACE risk was greater for participants with kidney impairment or damage than for those without. Semaglutide consistently reduced MACE risk across eGFR and UACR subgroups, indicating that semaglutide provides cardiovascular benefits in people with T2D and at high cardiovascular risk across a broad spectrum of kidney function and damage. Trial registrations NCT01720446; NCT02692716." @default.
• W4386119477 created "2023-08-25" @default.
• W4386119477 creator A5012676820 @default.
• W4386119477 creator A5022323276 @default.
• W4386119477 creator A5030492424 @default.
• W4386119477 creator A5031624913 @default.
• W4386119477 creator A5070579413 @default.
• W4386119477 creator A5079491558 @default.
• W4386119477 creator A5080463002 @default.
• W4386119477 date "2023-08-24" @default.
• W4386119477 modified "2023-10-16" @default.
• W4386119477 title "Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis" @default.
• W4386119477 cites W2033209427 @default.
• W4386119477 cites W2150959326 @default.
• W4386119477 cites W2155965977 @default.
• W4386119477 cites W2425644022 @default.
• W4386119477 cites W2519510391 @default.
• W4386119477 cites W2605440965 @default.
• W4386119477 cites W2607031541 @default.
• W4386119477 cites W2754041380 @default.
• W4386119477 cites W2803540340 @default.
• W4386119477 cites W2808008353 @default.
• W4386119477 cites W2901979245 @default.
• W4386119477 cites W2948612418 @default.
• W4386119477 cites W2968073288 @default.
• W4386119477 cites W2970412630 @default.
• W4386119477 cites W2970959072 @default.
• W4386119477 cites W2982342400 @default.
• W4386119477 cites W2989595227 @default.
• W4386119477 cites W2993963531 @default.
• W4386119477 cites W2998275298 @default.
• W4386119477 cites W3021290569 @default.
• W4386119477 cites W3021856094 @default.
• W4386119477 cites W3046891294 @default.
• W4386119477 cites W3097926417 @default.
• W4386119477 cites W3134100899 @default.
• W4386119477 cites W3163402894 @default.
• W4386119477 cites W3195404919 @default.
• W4386119477 cites W3204118678 @default.
• W4386119477 cites W4205388336 @default.
• W4386119477 cites W4206445899 @default.
• W4386119477 cites W4285820616 @default.
• W4386119477 cites W4289639427 @default.
• W4386119477 cites W4297021616 @default.
• W4386119477 cites W4300688387 @default.
• W4386119477 cites W4306783667 @default.
• W4386119477 cites W4312498949 @default.
• W4386119477 cites W4313656426 @default.
• W4386119477 cites W4317213523 @default.
• W4386119477 cites W4318980736 @default.
• W4386119477 doi "https://doi.org/10.1186/s12933-023-01949-7" @default.
• W4386119477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37620807" @default.
• W4386119477 hasPublicationYear "2023" @default.
• W4386119477 type Work @default.
• W4386119477 citedByCount "0" @default.
• W4386119477 crossrefType "journal-article" @default.
• W4386119477 hasAuthorship W4386119477A5012676820 @default.
• W4386119477 hasAuthorship W4386119477A5022323276 @default.
• W4386119477 hasAuthorship W4386119477A5030492424 @default.
• W4386119477 hasAuthorship W4386119477A5031624913 @default.
• W4386119477 hasAuthorship W4386119477A5070579413 @default.
• W4386119477 hasAuthorship W4386119477A5079491558 @default.
• W4386119477 hasAuthorship W4386119477A5080463002 @default.
• W4386119477 hasBestOaLocation W43861194771 @default.
• W4386119477 hasConcept C126322002 @default.
• W4386119477 hasConcept C126894567 @default.
• W4386119477 hasConcept C134018914 @default.
• W4386119477 hasConcept C159641895 @default.
• W4386119477 hasConcept C207103383 @default.
• W4386119477 hasConcept C2776174234 @default.
• W4386119477 hasConcept C2777180221 @default.
• W4386119477 hasConcept C2779284873 @default.
• W4386119477 hasConcept C2780739214 @default.
• W4386119477 hasConcept C2781308992 @default.
• W4386119477 hasConcept C2909862629 @default.
• W4386119477 hasConcept C44249647 @default.
• W4386119477 hasConcept C45393284 @default.
• W4386119477 hasConcept C500558357 @default.
• W4386119477 hasConcept C555293320 @default.
• W4386119477 hasConcept C67761136 @default.
• W4386119477 hasConcept C71924100 @default.
• W4386119477 hasConceptScore W4386119477C126322002 @default.
• W4386119477 hasConceptScore W4386119477C126894567 @default.
• W4386119477 hasConceptScore W4386119477C134018914 @default.
• W4386119477 hasConceptScore W4386119477C159641895 @default.
• W4386119477 hasConceptScore W4386119477C207103383 @default.
• W4386119477 hasConceptScore W4386119477C2776174234 @default.
• W4386119477 hasConceptScore W4386119477C2777180221 @default.
• W4386119477 hasConceptScore W4386119477C2779284873 @default.
• W4386119477 hasConceptScore W4386119477C2780739214 @default.
• W4386119477 hasConceptScore W4386119477C2781308992 @default.
• W4386119477 hasConceptScore W4386119477C2909862629 @default.
• W4386119477 hasConceptScore W4386119477C44249647 @default.
• W4386119477 hasConceptScore W4386119477C45393284 @default.
• W4386119477 hasConceptScore W4386119477C500558357 @default.
• W4386119477 hasConceptScore W4386119477C555293320 @default.
• W4386119477 hasConceptScore W4386119477C67761136 @default.
• W4386119477 hasConceptScore W4386119477C71924100 @default.
• W4386119477 hasIssue "1" @default.
• W4386119477 hasLocation W43861194771 @default.

• next